{
    "clinical_study": {
        "@rank": "107703", 
        "arm_group": [
            {
                "arm_group_label": "SPIROMAX", 
                "arm_group_type": "Active Comparator", 
                "description": "Period 1 of this study will comprise a single visit wherein mastery of inhaler technique will be assessed. Empty training devices will be utilized for this period. Period 2 dosage will be equivalent to that received via the participants current device at baseline.\nParticipants receiving 800 mcg to 1000 mcg budesonide diphosphate (BDP)-equivalent inhaled corticosteroids at study entry will receive budesonide and formoterol at daily doses of 640 mcg and 18 mcg, respectively."
            }, 
            {
                "arm_group_label": "TURBOHALER", 
                "arm_group_type": "Active Comparator", 
                "description": "Period 1 of this study will comprise a single visit wherein mastery of inhaler technique will be assessed. Empty training devices will be utilized for this period. Period 2 dosage will be equivalent to that received via the participants current device at baseline.\nParticipants receiving 1600 mcg to 2000 mcg budesonide diphosphate (BDP)-equivalent inhaled corticosteroids at study entry will receive budesonide and formoterol at daily doses of 1280 mcg and 36 mcg, respectively."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is conducted to assess whether training participants on proper use of BF SPIROMAX\n      and Symbicort TURBOHALER will improve their device-handling technique and potentially\n      improve their treatment outcome, ie, better asthma control."
        }, 
        "brief_title": "Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX\u00ae as Compared to SYMBICORT\u00ae TURBOHALER\u00ae as Treatment for Adult Patients With Asthma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent signed and dated by the adult patient before conducting any\n             study related procedures.\n\n          -  The patient is a man or woman 18 through 75 years of age as of the screening visit.\n\n          -  The patient has a diagnosis of asthma in accordance with Global Initiative for Asthma\n             (GINA) criteria as evidenced by a United Kingdom (UK) quality outcome framework\n             approved Read code (UK diagnostic coding system).\n\n          -  The patient is receiving step 3 or 4 therapy for asthma as defined by the British\n             Thoracic Society (BTS) guidelines (daily doses of BDP-equivalent inhaled\n             corticosteroid (ICS) \u2265800 mcg to 2000 mcg as part of fixed or free combinations with\n             long-acting beta-agonists (LABA).\n\n          -  If patient is a female of childbearing potential (postmenarche or less than 2 years\n             post-menopausal or not surgically sterile) the patient must be willing to commit to\n             using a medically accepted method of contraception for the duration of study and 30\n             days after discontinuing study drug.\n\n          -  The patient, as judged by the investigator, must be willing and able to understand\n             risks and benefits of study participation to give informed consent and to comply with\n             all study requirements as specified in this protocol for the entire duration of their\n             study participation.\n\n          -  The patient is SPIROMAX and TURBOHALER na\u00efve (no use of a TURBOHALER device in the\n             last 6 months, minimizing carryover from prior device use).\n\n          -  If female, the patient must have a negative urine pregnancy test. o other criteria\n             apply, please contact the investigator for additional information\n\n        Exclusion Criteria:\n\n          -  The patient has any clinically significant uncontrolled medical condition (treated or\n             untreated) that, in the judgment of the investigator, will cause participation in the\n             study to be detrimental to the patient.\n\n          -  The patient has participated in a Teva sponsored clinical study with BF SPIROMAX in\n             the last 6 months.\n\n          -  The patient is a pregnant, attempting to become pregnant, or breast feeding. (Any\n             woman becoming pregnant during the study will be withdrawn from the study.)\n\n          -  The patient has used a clinical trial investigational drug within 1 month before the\n             screening visit.\n\n          -  The patient has an ongoing asthma exacerbation or has received OCS and/or antibiotics\n             for a lower respiratory condition (proxy measure for identifying an asthma\n             exacerbation and/or lower respiratory infection, suggestive of altered inspiratory\n             capabilities) in the 2 weeks preceding visit\n\n          -  The patient is currently receiving any OCS (including long or short courses).\n\n          -  The patient has a significant chronic lower respiratory tract disease other than\n             asthma eg chronic obstructive pulmonary disease (COPD), cystic fibrosis or\n             interstitial lung disease. Conditions that are not predominant, such as minor degrees\n             of bronchiectasis, are not a reason for exclusion.\n\n          -  The patient has a known allergy or severe sensitivity to the constituents of the\n             study drugs (SPIROMAX or TURBOHALER) eg, to lactose or to milk protein.\n\n               -  other criteria apply, please contact the investigator for additional information"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062463", 
            "org_study_id": "BFS-AS-40035", 
            "secondary_id": "2013-004630-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "SPIROMAX", 
                "description": "SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 mcg)", 
                "intervention_name": "Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX", 
                "intervention_type": "Drug", 
                "other_name": "SPIROMAX\u00ae"
            }, 
            {
                "arm_group_label": "TURBOHALER", 
                "description": "SYMBICORT\u00ae  TURBOHALER\u00ae (200/6 and 400/12 mcg)", 
                "intervention_name": "SYMBICORT TURBOHALER budesonide and formoterol fumarate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "SYMBICORT\u00ae", 
                    "TURBOHALER\u00ae"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Budesonide", 
                "Formoterol", 
                "Symbicort"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Asthma", 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Babbacombe", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34081"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burnhope", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34066"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bury St Edmunds", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34064"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cheltenham", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34072"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chippenham", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34063"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daventry", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34075"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Hunsbury", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34083"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harrogate", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34079"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harrogate", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34068"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liskeard", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34082"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Loughborough", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34080"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louth", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34087"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lowestoft", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34086"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34076"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oadby", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34085"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oldham", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34070"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Redditch", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34089"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stowmarket", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34065"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strensall", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34067"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Swindon", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34078"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Trowbridge", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34088"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Trowbridge", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34077"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waterlooville", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34073"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waterlooville", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34071"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wells-Next-Sea", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34084"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Woodbridge", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34074"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Woodbridge", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Teva Investigational Site 34069"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 12 Week, Randomized, Open-Label, Parallel Group Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX\u00ae (160/4.5 and 320/9 mcg) as Compared to SYMBICORT\u00ae TURBOHALER\u00ae (200/6 and 400/12 mcg) as Treatment for Adult Patients With Asthma", 
        "overall_contact": {
            "last_name": "Teva US Medical Information", 
            "phone": "1-800-896-5855"
        }, 
        "overall_official": {
            "affiliation": "TEVA", 
            "last_name": "Sponsor's Medical Expert, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Total observed critical errors (technology and handling)", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Treatment Adherence according to 6 step standardized device training", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062463"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Observed number of steps taken to achieve device mastery", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "description": "Fourteen questions which may be scored with answers that range from Very Dissatisfied to Very Satisfied", 
                "measure": "Patient Satisfaction and Preference Questionnaire (PASAPQ) score", 
                "safety_issue": "No", 
                "time_frame": "4 Months"
            }, 
            {
                "measure": "Number of different handling errors identified following training", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "description": "7 questions, generating a value from 0 (totally controlled) to 6 (severely uncontrolled)", 
                "measure": "Change from baseline in the 6-item ASTHMA CONTROL QUESTIONNAIRE (ACQ)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, week 4, 8, and 12"
            }, 
            {
                "measure": "Number of participants with change in Asthma Treatment", 
                "safety_issue": "No", 
                "time_frame": "4 Months"
            }, 
            {
                "measure": "Number of severe asthma exacerbations", 
                "safety_issue": "No", 
                "time_frame": "4 Months"
            }, 
            {
                "measure": "Summary of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "4 Months"
            }
        ], 
        "source": "Teva Pharmaceutical Industries", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Teva Branded Pharmaceutical Products, R&D Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}